[go: up one dir, main page]

NO316863B1 - Oral farmasoytisk, tablettert multippel enhetsdoseringsfom, fremgangsmate for dens fremstilling, anvendelse derav, og blaerepakning - Google Patents

Oral farmasoytisk, tablettert multippel enhetsdoseringsfom, fremgangsmate for dens fremstilling, anvendelse derav, og blaerepakning Download PDF

Info

Publication number
NO316863B1
NO316863B1 NO19960948A NO960948A NO316863B1 NO 316863 B1 NO316863 B1 NO 316863B1 NO 19960948 A NO19960948 A NO 19960948A NO 960948 A NO960948 A NO 960948A NO 316863 B1 NO316863 B1 NO 316863B1
Authority
NO
Norway
Prior art keywords
dosage form
coating layer
enteric coating
tableted
units
Prior art date
Application number
NO19960948A
Other languages
English (en)
Norwegian (no)
Other versions
NO960948D0 (no
NO960948L (no
Inventor
Kurt Ingmar Lovgren
Pontus John Arvid Bergstrand
Original Assignee
Astrazeneca Ab Global Ip
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20394685&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO316863(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab Global Ip filed Critical Astrazeneca Ab Global Ip
Publication of NO960948D0 publication Critical patent/NO960948D0/no
Publication of NO960948L publication Critical patent/NO960948L/no
Publication of NO316863B1 publication Critical patent/NO316863B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO19960948A 1994-07-08 1996-03-07 Oral farmasoytisk, tablettert multippel enhetsdoseringsfom, fremgangsmate for dens fremstilling, anvendelse derav, og blaerepakning NO316863B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9402431A SE9402431D0 (sv) 1994-07-08 1994-07-08 New tablet formulation
PCT/SE1995/000678 WO1996001624A1 (fr) 1994-07-08 1995-06-07 Preparation pharmaceutique composite renfermant un inhibiteur de pompe a protons

Publications (3)

Publication Number Publication Date
NO960948D0 NO960948D0 (no) 1996-03-07
NO960948L NO960948L (no) 1996-03-07
NO316863B1 true NO316863B1 (no) 2004-06-07

Family

ID=20394685

Family Applications (2)

Application Number Title Priority Date Filing Date
NO960949A NO960949D0 (no) 1994-07-08 1996-03-07 Tablettert flerdoseenhetsform inneholdende protonpumpeinhibitor
NO19960948A NO316863B1 (no) 1994-07-08 1996-03-07 Oral farmasoytisk, tablettert multippel enhetsdoseringsfom, fremgangsmate for dens fremstilling, anvendelse derav, og blaerepakning

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO960949A NO960949D0 (no) 1994-07-08 1996-03-07 Tablettert flerdoseenhetsform inneholdende protonpumpeinhibitor

Country Status (35)

Country Link
US (1) US5753265A (fr)
EP (3) EP1452172A3 (fr)
JP (2) JP3878669B2 (fr)
KR (1) KR100384961B1 (fr)
CN (2) CN1134667A (fr)
AT (1) ATE275396T1 (fr)
AU (1) AU695971B2 (fr)
BR (2) BR9506029A (fr)
CA (2) CA2170644C (fr)
CZ (1) CZ294380B6 (fr)
DE (1) DE69533470T2 (fr)
DK (1) DK0723437T3 (fr)
EE (1) EE03292B1 (fr)
ES (1) ES2227556T3 (fr)
FI (2) FI961059L (fr)
HU (2) HUT75934A (fr)
IL (2) IL114447A (fr)
IS (3) IS4326A (fr)
MA (1) MA23608A1 (fr)
MY (1) MY114388A (fr)
NO (2) NO960949D0 (fr)
NZ (1) NZ289949A (fr)
PL (2) PL180598B1 (fr)
PT (1) PT723437E (fr)
RU (2) RU2538511C2 (fr)
SA (1) SA95160092B1 (fr)
SE (1) SE9402431D0 (fr)
SI (1) SI0723437T1 (fr)
SK (1) SK283841B6 (fr)
TN (1) TNSN95076A1 (fr)
TR (2) TR199500825A2 (fr)
TW (1) TW421599B (fr)
UA (1) UA47390C2 (fr)
WO (2) WO1996001625A1 (fr)
ZA (2) ZA955547B (fr)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
US5817338A (en) * 1994-07-08 1998-10-06 Astra Aktiebolag Multiple unit tableted dosage form of omeprazole
ES2094694B1 (es) * 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
HU227566B1 (en) * 1995-09-21 2011-08-29 Pharma Pass Llc Acid-labile pharmaceutical composition containing omeprazole and process for its preparation
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE9602442D0 (sv) * 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals
US6623759B2 (en) * 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
HUP0100179A3 (en) 1997-07-03 2002-12-28 Bristol Myers Squibb Pharma Co Imidazopyrimidine and imidazopyridine derivatives and pharmaceutical compositions thereof
ES2137862B1 (es) * 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
US20050244497A1 (en) * 1997-11-05 2005-11-03 Wockhardt Limited Delayed delivery system for acid-sensitive drugs
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6602522B1 (en) * 1997-11-14 2003-08-05 Andrx Pharmaceuticals L.L.C. Pharmaceutical formulation for acid-labile compounds
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
DE69821976T2 (de) * 1997-12-08 2004-12-16 Altana Pharma Ag Neue suppositoriumsform mit säureempfindliche wirkstoffe
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
FR2774288B1 (fr) 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
DK1736144T3 (en) 1998-05-18 2015-12-07 Takeda Pharmaceutical Orally disintegrating tablets.
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
TWI257311B (en) 1998-07-28 2006-07-01 Takeda Chemical Industries Ltd Rapidly disintegrable solid preparation
EP1105105B1 (fr) 1998-08-12 2006-03-29 ALTANA Pharma AG Forme d'administration orale des pyridin-2-ylmethylsulfinyl-1h-benzimidazoles -
US6733778B1 (en) * 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
WO2000026185A2 (fr) * 1998-10-30 2000-05-11 The Curators Of The University Of Missouri Solution d'omeprazole et methode d'utilisation associee
CN100503598C (zh) * 1998-11-18 2009-06-24 阿斯特拉曾尼卡有限公司 改进的化学方法和药物制剂
US6174902B1 (en) 1999-04-28 2001-01-16 Sepracor Inc. R-rabeprazole compositions and methods
FR2793688B1 (fr) * 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
SI1187601T1 (sl) 1999-06-07 2005-12-31 Altana Pharma Ag Novi pripravek in dajalna oblika, ki obsega kislinsko labilen inhibitor protonske crpalke
IL130602A0 (en) * 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
ES2168043B1 (es) * 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
US6743820B2 (en) 2000-07-07 2004-06-01 University Of Toledo Methods for protection of stratified squamous epithelium against injury by noxious substances and novel agents for use therefor
AU2001296908A1 (en) * 2000-09-29 2002-04-08 Geneva Pharmaceuticals, Inc. Proton pump inhibitor formulation
PT1341528E (pt) 2000-12-07 2012-03-20 Nycomed Gmbh Comprimido de desintegração rápida compreendendo um ingrediente activo lábil a ácido
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
RU2197266C1 (ru) * 2001-06-01 2003-01-27 Эпштейн Олег Ильич Лекарственное средство и способ лечения эрозивных и воспалительных заболеваний желудочно-кишечного тракта
US8765176B2 (en) 2001-06-20 2014-07-01 Takeda Pharmaceutical Campany Limited Method of manufacturing tablet
JP5138856B2 (ja) * 2001-06-20 2013-02-06 武田薬品工業株式会社 錠剤の製造方法
BR0206086A (pt) * 2001-09-28 2003-12-23 Mcneil Ppc Inc Formas de dosagem de liberação modificada
JP2006282677A (ja) * 2001-10-17 2006-10-19 Takeda Chem Ind Ltd 酸に不安定な薬物の高含量顆粒
JP4331930B2 (ja) * 2001-10-17 2009-09-16 武田薬品工業株式会社 酸に不安定な薬物の高含量顆粒
US8105626B2 (en) 2001-10-17 2012-01-31 Takeda Pharmaceutical Company Limited Granules containing acid-unstable chemical in large amount
ES2198195B1 (es) * 2001-12-18 2004-10-01 Laboratorios Del Dr. Esteve, S.A. Forma de dosificacion farmaceutica oral comprimida, con recubrimiento enterico, que contiene un compuesto de bencimidazol labil en medio acido.
US20040006111A1 (en) * 2002-01-25 2004-01-08 Kenneth Widder Transmucosal delivery of proton pump inhibitors
US7125563B2 (en) * 2002-04-12 2006-10-24 Dava Pharmaceuticals, Inc. Sustained release pharmaceutical preparations and methods for producing the same
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
US6902746B2 (en) * 2002-07-03 2005-06-07 Yung Shin Pharmaceutical Industrial Co., Ltd. Oral pharmaceutical compositions containing non-steroidal anti-inflammatory drugs and method for preparing the same
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
FR2845289B1 (fr) 2002-10-04 2004-12-03 Ethypharm Sa Spheroides, procede de preparation et compositions pharmaceutiques.
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
FR2845917B1 (fr) * 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire
US9107804B2 (en) 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20040166162A1 (en) * 2003-01-24 2004-08-26 Robert Niecestro Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
WO2004066982A1 (fr) * 2003-01-31 2004-08-12 Ranbaxy Laboratories Limited Compositions orales stables de benzimidazole et leurs procedes de preparation
EP1603537A4 (fr) * 2003-02-20 2009-11-04 Santarus Inc Liberation immediate d'un complexe antacide d'omeprazole presentant une nouvelle formulation pour une elimination rapide et prolongee d'acide gastrique
CA2512928A1 (fr) * 2003-02-24 2004-09-02 Mitsubishi Pharma Corporation Enantiomere de tenatoprazole et son utilisation dans une therapie
US20040213847A1 (en) * 2003-04-23 2004-10-28 Matharu Amol Singh Delayed release pharmaceutical compositions containing proton pump inhibitors
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
WO2004112756A1 (fr) 2003-06-26 2004-12-29 Isa Odidi Capsules contenant un inhibiteur de la pompe a protons comprenant des unites secondaires differemment structurees permettant une liberation retardee de l'ingredient actif
US20070053981A1 (en) * 2003-07-11 2007-03-08 Eva Blychert Solid composition comprising a proton pump inhibitor
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050037070A1 (en) * 2003-07-18 2005-02-17 Santarus, Inc. Pharmaceutical formulatins useful for inhibiting acid secretion and methods for making and using them
TWI337877B (en) * 2003-07-18 2011-03-01 Santarus Inc Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
JP2005306778A (ja) * 2004-04-21 2005-11-04 Basf Ag 徐放性製剤及びその製造方法
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1753405A4 (fr) * 2004-06-10 2008-09-17 Glatt Air Tech Inc Preparation pharmaceutique a liberation lente
AU2005264864B2 (en) 2004-06-16 2011-08-11 Takeda Pharmaceutical Company Limited Multiple PPI dosage form
FR2871800B1 (fr) * 2004-06-17 2006-08-25 Sidem Pharma Sa Sa Sel de sodium monohydrate du s-tenatoprazole et application en therapeutique
US20050281876A1 (en) 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US20060134210A1 (en) * 2004-12-22 2006-06-22 Astrazeneca Ab Solid dosage form comprising proton pump inhibitor and suspension made thereof
US8673352B2 (en) * 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
EP1813275A1 (fr) * 2005-12-20 2007-08-01 Teva Pharmaceutical Industries Ltd Comprime oral desintegrable de lansoprazole
US20070141151A1 (en) * 2005-12-20 2007-06-21 Silver David I Lansoprazole orally disintegrating tablets
WO2007075980A2 (fr) * 2005-12-20 2007-07-05 Teva Pharmaceutical Industries Ltd. Comprimes de lansoprazole se desintegrant oralement
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CN101389316A (zh) * 2005-12-28 2009-03-18 武田药品工业株式会社 控制释放固体制剂
WO2007078874A2 (fr) * 2005-12-30 2007-07-12 Cogentus Pharmaceuticals, Inc. Formulations pharmaceutiques à usage oral contenant des médicaments anti-inflammatoires non stéroïdiens et des inhibiteurs d'acides
EP2007360B1 (fr) * 2006-04-03 2014-11-26 Isa Odidi Dispositif d'administration à libération commandée comprenant un enrobage organosol
US9532945B2 (en) * 2006-04-04 2017-01-03 Kg Acquisition Llc Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
CA2647497C (fr) * 2006-04-04 2016-01-12 Cogentus Pharmaceuticals, Inc. Formes de dosage orales incluant un inhibiteur de l'agregation plaquettaire et un inhibiteur acide
US20090068263A1 (en) * 2006-04-20 2009-03-12 Themis Laboratories Private Limited Multiple unit compositions
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
WO2007138606A2 (fr) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Formulation pharmaceutique comprenant des unités multiples
CN101500553B (zh) * 2006-07-25 2012-04-18 维克塔有限公司 联合使用小分子二羧酸的衍生物与ppi用于抑制胃酸分泌的组合物和方法
RU2009106681A (ru) * 2006-07-28 2010-09-10 Др.Редди`С Лабораторис Лтд. (In) Гранулированные фармацевтические композиции
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
TR200605624A2 (tr) * 2006-10-10 2008-05-21 Nobel İlaç Sanayi̇ Ve Ti̇caret Aş. Farmasötik dozaj şekli
EP2086543A2 (fr) 2006-10-27 2009-08-12 The Curators of the University of Missouri Compositions comprenant des agents d'inhibition de la pompe à protons labiles d'acide, au moins un autre agent pharmaceutiquement actif et leurs procédés d'utilisation
US8352042B2 (en) * 2006-11-28 2013-01-08 The Alfred E. Mann Foundation For Scientific Research Remote controls and ambulatory medical systems including the same
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
DE102007009242A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit magensaftresistenter Wirkstoff-Matix
EP2044932A1 (fr) * 2007-10-04 2009-04-08 Laboratorios del Dr. Esteve S.A. Couche de protection mécanique pour formes de dosages solides
KR20170097787A (ko) 2007-10-12 2017-08-28 다케다 파마슈티칼스 유에스에이, 인코포레이티드 음식 섭취와 관계없이 위장 장애를 치료하는 방법
US8247440B2 (en) 2008-02-20 2012-08-21 Curators Of The University Of Missouri Composition comprising omeprazole, lansoprazole and at least one buffering agent
CN102026627B (zh) 2008-03-11 2016-10-26 武田药品工业株式会社 口腔崩解固体制剂
TWI519322B (zh) * 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 包含弱鹼性藥物及控制釋放劑型之組合物
US20090280175A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Proton Pump Inhibitor Tablets
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
EP2345408A3 (fr) 2010-01-08 2012-02-29 Dr. Reddy's Laboratories Ltd. Formulations de médicament labiles acides
MX346316B (es) 2010-02-25 2017-03-15 Evonik Roehm Gmbh Formulacion farmaceutica o nutraceutica.
US20130202688A1 (en) 2010-05-04 2013-08-08 Sunilendu Bhushan Roy Delayed release oral disintegrating pharmaceutical compositions of lansoprazole
PH12013500039A1 (en) 2010-07-22 2013-02-18 Lupin Ltd Multiple unit tablet composition
IT1401284B1 (it) * 2010-08-06 2013-07-18 Valpharma S P A Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system).
EP2468263A1 (fr) * 2010-12-23 2012-06-27 Laboratorios Del. Dr. Esteve, S.A. Formes de dosage solides compressées
CN102805735A (zh) * 2011-06-21 2012-12-05 寿光富康制药有限公司 一种埃索美拉唑肠溶微丸片及其制备方法
HRP20180567T1 (hr) * 2011-11-02 2018-05-18 Laboratorios Del Dr. Esteve, S.A. Farmaceutski pripravak omeprazola
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
EP3288556A4 (fr) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Compositions à désintégration par voie orale
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CZ2017315A3 (cs) 2017-06-02 2018-12-12 Zentiva, K.S. Dávkovací jednotka s PPI (inhibitory protonové pumpy)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) * 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
SE450087B (sv) * 1985-10-11 1987-06-09 Haessle Ab Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US4710384A (en) * 1986-07-28 1987-12-01 Avner Rotman Sustained release tablets made from microcapsules
GB8630080D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
SE8803822D0 (sv) * 1988-10-26 1988-10-26 Novel dosage form
SE8804629D0 (sv) * 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
EP0593463B1 (fr) * 1990-06-20 1999-09-15 Astra Aktiebolag Derives de dialcoxy-pyridinyle-benzimidazole, procede de preparation et utilisation pharmaceutique de ces derives
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
EP0519144B1 (fr) * 1991-06-21 1997-08-13 Ilsan Ilac Ve Hammaddeleri Sanayi A.S. Nouveau procédé galenique pour des pellets contenant de l'oméprazole
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
PT723777E (pt) * 1993-10-12 2002-11-29 Mitsubishi Pharma Corp Comprimido contendo granulos entericos
US5817338A (en) * 1994-07-08 1998-10-06 Astra Aktiebolag Multiple unit tableted dosage form of omeprazole
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation

Also Published As

Publication number Publication date
PT723437E (pt) 2004-12-31
NO960948D0 (no) 1996-03-07
IS4328A (is) 1996-03-04
TR199500825A2 (tr) 1996-06-21
HUT75934A (en) 1997-05-28
WO1996001624A1 (fr) 1996-01-25
PL313389A1 (en) 1996-06-24
EE03292B1 (et) 2000-10-16
PL313388A1 (en) 1996-06-24
CZ73096A3 (en) 1996-07-17
NO960949L (no) 1996-03-07
SI0723437T1 (en) 2005-02-28
JPH09502740A (ja) 1997-03-18
TW421599B (en) 2001-02-11
FI122016B (fi) 2011-07-29
JPH09502741A (ja) 1997-03-18
MA23608A1 (fr) 1996-04-01
IL114447A0 (en) 1995-11-27
IL114449A0 (en) 1995-11-27
CA2170644C (fr) 2011-02-22
DK0723437T3 (da) 2004-12-13
CN1134668A (zh) 1996-10-30
UA47390C2 (uk) 2002-07-15
IL114447A (en) 2002-09-12
EP1452172A3 (fr) 2004-11-03
BR9506029A (pt) 1997-10-14
FI961059A7 (fi) 1996-03-07
EP0724434A1 (fr) 1996-08-07
HK1008298A1 (en) 1999-05-07
US5753265A (en) 1998-05-19
SA95160092B1 (ar) 2006-06-20
NO960949D0 (no) 1996-03-07
FI961058A0 (fi) 1996-03-07
MX9600856A (es) 1997-10-31
CN1134667A (zh) 1996-10-30
BR9506028A (pt) 1997-10-14
AU2993895A (en) 1996-02-09
KR100384961B1 (ko) 2003-08-25
AU695971B2 (en) 1998-08-27
SK283841B6 (sk) 2004-03-02
CA2170995A1 (fr) 1996-01-26
CA2170644A1 (fr) 1996-01-25
NZ289949A (en) 1997-07-27
TNSN95076A1 (fr) 1996-02-06
IS4326A (is) 1996-03-04
SK30096A3 (en) 1997-09-10
ZA955546B (en) 1996-01-08
MY114388A (en) 2002-10-31
JP3878669B2 (ja) 2007-02-07
RU2538511C2 (ru) 2015-01-10
ATE275396T1 (de) 2004-09-15
ZA955547B (en) 1996-01-08
EP1452172A2 (fr) 2004-09-01
CZ294380B6 (cs) 2004-12-15
DE69533470T2 (de) 2005-09-22
SE9402431D0 (sv) 1994-07-08
HU9600572D0 (en) 1996-05-28
FI961059A0 (fi) 1996-03-07
PL180598B1 (pl) 2001-03-30
TR199500826A2 (tr) 1996-06-21
WO1996001625A1 (fr) 1996-01-25
ES2227556T3 (es) 2005-04-01
IS4329A (is) 1996-03-04
FI961059L (fi) 1996-03-07
EP0723437A1 (fr) 1996-07-31
HU9600574D0 (en) 1996-05-28
CN1152671C (zh) 2004-06-09
FI961058L (fi) 1996-03-07
EP0723437B1 (fr) 2004-09-08
DE69533470D1 (de) 2004-10-14
RU2166935C2 (ru) 2001-05-20
NO960948L (no) 1996-03-07

Similar Documents

Publication Publication Date Title
NO316863B1 (no) Oral farmasoytisk, tablettert multippel enhetsdoseringsfom, fremgangsmate for dens fremstilling, anvendelse derav, og blaerepakning
EP0723436B1 (fr) Forme posologique sous forme de comprime composite (i)
NO326656B1 (no) Orale, farmasoytiske doseringsformer innbefattende en protonpumpeinhibitor og et syrenoytraliserende middel eller alginat, fremgangsmate for fremstilling av slike doseringsformer og anvendelse derav.
NO319999B1 (no) Tabletterte, brusende multippelenhet-doseringsformer omfattende en protonpumpeinhibitor, fremgangsmate for fremstilling av slike doseringsformer, og anvendelse derav.
NO320056B1 (no) Farmasoytisk formulering innbefattende omeprazol, fremgangsmate til fremstilling derav, anvendelse av HPC i formuleringen, samt anvendelse av formuleringen til behandling av gastrointestinale sykdommer.
KR20230079406A (ko) 장용성 펠렛, 이의 제조 방법 및 이를 포함하는 제제
MXPA96000856A (en) Pharmaceutical preparation of multiple units, which contain an inhibitor of the proto pump
HK1008298B (en) Multiple unit pharmaceutical preparation containing proton pump inhibitor
AU2993995A (en) Multiple unit tableted dosage form containing proton pump inhibitor
HK1008300B (en) Multiple unit tableted dosage form 1

Legal Events

Date Code Title Description
MK1K Patent expired